Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804
Q1 FY22 results · Apr–Jun 2021
Aurobindo Pharma reported revenue from operations of ₹5,701.98 crore (down 3.8% from Q1 FY21) and net profit of ₹769.97 crore (down 1.4% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 5,701.98 | 5,924.78 | −3.8% | 6,001.50 | −5.0% |
| Other income | 81.31 | 115.59 | −29.7% | 78.10 | +4.1% |
| Total income | 5,783.29 | 6,040.37 | −4.3% | 6,079.60 | −4.9% |
| Profit before share of associates & JVs and tax | 1,026.71 | 1,096.35 | −6.4% | 1,069.24 | −4.0% |
| Share of profit/(loss) of associates & JVs | (9.00) | (12.00) | (8.37) | ||
| Net profit for the period | 769.97 | 780.68 | −1.4% | 801.18 | −3.9% |
| EPS, basic (₹) | 13.14 | 13.32 | −1.4% | 13.67 | −3.9% |
| Net margin (%) | 13.5 | 13.2 | 13.3 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,893.75 | 3,419.70 | −15.4% | 4,114.03 | −29.7% |
| Other income | 27.03 | 125.58 | −78.5% | 267.42 | −89.9% |
| Total income | 2,920.78 | 3,545.28 | −17.6% | 4,381.45 | −33.3% |
| Profit before tax | 335.05 | 960.19 | −65.1% | 1,113.45 | −69.9% |
| Net profit for the period | 215.07 | 714.68 | −69.9% | 872.58 | −75.4% |
| EPS, basic (₹) | 3.67 | 12.20 | −69.9% | 14.89 | −75.4% |
| Net margin (%) | 7.4 | 20.9 | 21.2 |
Consolidated
- Filed with BSE
- 13 Aug 2021, 08:49 IST
- Board meeting
- 12 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2021, 08:49 IST
- Board meeting
- 12 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE